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Neurogenic bladder is a general term encompassing various neurologic dysfunctions of  the bladder and the external urethral 
sphincter. These can be caused by damage or disease. Therapeutic management options can be conservative, minimally invasive, 
or surgical. The current standard for surgical management is bladder augmentation using intestinal segments. However, because 
intestinal tissue possesses different functional characteristics than bladder tissue, numerous complications can ensue, including 
excess mucus production, urinary stone formation, and malignancy. As a result, investigators have sought after alternative solu-
tions. Tissue engineering is a scientific field that uses combinations of cells and biomaterials to encourage regeneration of new, 
healthy tissue and offers an alternative approach for the replacement of lost or deficient organs, including the bladder. Promising 
results using tissue-engineered bladder have already been obtained in children with neurogenic bladder caused by myelomenin-
gocele. Human clinical trials, governed by the Food and Drug Administration, are ongoing in the United States in both children 
and adults to further evaluate the safety and efficacy of this technology. This review will introduce the principles of tissue engi-
neering and discuss how it can be used to treat refractory cases of neurogenic bladder. 
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INTRODUCTION
Many disorders of the genitourinary tract can become severe 
enough to eventually require reconstruction. These include 
congenital disorders such as myelomenigocele or bladder exstro-
phy, bladder cancer, trauma, and chronic inflammation resulting 
from interstitial cystitis or other conditions. In addition to struc-
tural damage, insult to the nerves that innervate the bladder can 
also lead to bladder dysfunction that is severe enough to warrant 
surgical intervention and eventual reconstruction of the lower 
urinary tract. The term “neurogenic bladder” is used to describe 
these alterations in bladder function that are provoked by neu-
rologic dysfunction that results from disease or injury, and this 
condition often significantly increases the morbidity of the un-
derlying condition [1]. For example, pathologies that occur at 
or above the brain stem may cause neurogenic bladder (e.g., 
cerebrovascular disease, cerebral palsy, Parkinson’s disease, 
traumatic brain injuries, and brain tumors). In addition, pa-
thologies involving the spinal cord (e.g., sacral agenesis, teth-
ered spinal cord, traumatic cord injuries, multiple sclerosis, and 
transverse myelitis) may also lead to neurogenic bladder dys-
function [2,3]. The most common cause of neurogenic bladder 
in children is spina bifida, which affects one in one thousand 
newborns [4]. 
  Bladder dysfunction associated with neurogenic bladder may 
manifest in different ways [5]. Symptoms of neurogenic bladder 
range from severe urinary retention to incontinence, and result 
from detrusor underactivity to overactivity, depending on the 
site of neurologic insult. The urinary sphincter also may be af-
fected, resulting in sphincter underactivity or overactivity and 
loss of coordination with bladder function [6,7]. Urodynamic 
evaluation is important to define aspects of bladder and sphinc-
ter function such as bladder overactivity or underactivity associ-
ated with either sphincter synergy or dyssynergy [2]. The most 
Review Article
http://dx.doi.org/10.5213/inj.2011.15.3.109
pISSN 2093-4777 · eISSN 2093-6931110    www.einj.or.kr
Yoo, et al.  •  Engineering Bladder Tissue
http://dx.doi.org/10.5213/inj.2011.15.3.109
INJ
serious situations occur with high intravesical or leaking pres-
sures (above 40 cmH2O) and detrusor-sphincter dyssynergy 
because they represent a potential risk for upper tract deteriora-
tion. Children with myelomeningocele and neuropathic blad-
der, if not managed properly, face a ≥50% risk for upper uri-
nary tract deterioration [8,9]. In these cases, conventional man-
agement often consists of pharmacotherapy and frequent cath-
eterization to reduce intravesical pressure and maintain renal 
function, which can lead to mechanical damage to the urethra 
and frequent urinary tract infections. In addition, both reten-
tion and incontinence considerably decrease the quality of life 
of the patient [7]. Controlling, or at least minimizing, urinary 
incontinence and urinary tract infections facilitate the patients’ 
social inclusion and rehabilitation [5,10]. Treatment for neuro-
genic bladder can also be surgical; some of these options are 
minimally invasive (e.g., Botox injections and neurostimulator 
implants) and some are more invasive and reconstructive in na-
ture. In the latter case the diseased bladder is augmented with a 
bladder dome built from intestinal tissue. This reconstructive 
surgery is frequently performed in infants to prevent or delay 
the need for dialysis or kidney transplantation. However, use of 
intestinal segments in the urinary tract carries significant risks, 
such as excessive mucus production, urolithiasis, metabolic dis-
turbances, and malignancy [2,10,11].
  Because of the problems encountered with the use of gastro-
intestinal segments, numerous investigators have attempted al-
ternative reconstructive procedures. These have included auto-
augmentation [12,13] and ureterocystoplasty [14-16], but nei-
ther of these techniques has been entirely successful. Thus, nov-
el methods for bladder reconstruction based on the relatively 
new field of regenerative medicine are being explored. The term 
“regenerative medicine” was coined in 1999 by William Hasel-
tine, who was then the Scientific Founder and Chief Executive 
Officer of Human Genome Sciences [17]. The field of regenera-
tive medicine combines the areas of stem cell biology, cloning, 
cell transplantation, and tissue engineering with the goal of re-
generating living tissues and organs. This review focuses specif-
ically on the novel tissue engineering-based regenerative strate-
gies that are being applied to bladder reconstruction, and dis-
cusses how they can be used to treat the neurogenic bladder.
THE BASICS OF TISSUE ENGINEERING
Tissue engineering employs aspects of cell biology and trans-
plantation, materials science, and biomedical engineering to 
develop biological substitutes that can restore and maintain the 
normal function of damaged tissues and organs. These include 
injection of functional cells into a nonfunctional site to stimu-
late regeneration and the use of biocompatible materials to cre-
ate new tissues and organs. The introduction of cells is designed 
to stimulate regeneration, promote vascularization, and/or sup-
plement the production of hormones and growth factors. Bio-
materials, which include both natural and synthetic matrices 
that are commonly called scaffolds, are important tools in re-
generative medicine. In addition to guiding the direction of 
new tissue growth and providing the proper spatial environment 
to restore tissue structure and function, biomaterials may intro-
duce bioactive factors [18,19] or may attract cells and factors 
from the body following implantation [20,21]. If a biomaterial 
is implanted without cells, the objective is to encourage the body’s 
natural ability to repair itself.
Biomaterials Used in Genitourinary Tissue Construction
Synthetic materials have been used widely for urologic recon-
struction. Silicone prostheses have been used for the treatment 
of urinary incontinence with the artificial urinary sphincter and 
detachable balloon system, for treatment of vesicoureteral reflux 
with silicone microparticles, and for impotence with penile 
prostheses [22-24]. There has also been a major effort directed 
toward the construction of artificial bladders made with sili-
cone. In some disease states, such as urinary incontinence or 
vesicoureteral reflux, artificial agents (Teflon paste, glass mic-
roparticles) have been used as injectable bulking substances; 
however, these substances are not entirely biocompatible. 
  For regenerative medicine purposes, there are clear advan-
tages to using degradable, biocompatible materials that possess 
similar physical properties to native tissue and promote cellular 
interaction and tissue development [20,21,25]. Three different 
classes of biomaterials are used in regenerative medicine: natu-
rally derived materials (e.g., collagen, keratin, and alginate), 
acellular tissue matrices (e.g., decellularized submucosa from 
bladder or small-intestinal tissue), and synthetic polymers (e.g., 
polyglycolic acid [PGA], polyactic acid, and polylactic-cogly-
colic acid). Naturally-derived materials and decellularized tis-
sue matrices are considered to have biological properties that 
better mimic native tissue or organ extracellular matrix (and 
are thought to elicit fewer immune responses), but these are 
limited in supply and have compositions that are difficult to 
control or even characterize. On the other hand, synthetic scaf-
folds can be produced on a large scale with controlled proper-www.einj.or.kr    111
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ties of strength, microstructure and degradation rate.
Cells for Urogenital Tissue Engineering Applications
Often, when cells are used for tissue engineering, donor tissue 
is removed and dissociated into individual cells, which are then 
either implanted directly back into the host or expanded in cul-
ture, attached to a support matrix, and then implanted. Ideally, 
this approach allows lost tissue function to be restored or re-
placed in toto with limited complications [26-31]. The donor 
tissue used for this purpose can be heterologous, allogeneic, or 
autologous. 
  Autologous cells are the ideal choice, as their use circumvents 
many of the inflammatory and rejection issues associated with 
a non-self donor. In the past, one of the limitations of applying 
cell-based regenerative medicine techniques to organ replace-
ment was the inherent difficulty of growing certain human cell 
types in large quantities. However, the discovery of native tar-
geted progenitor cells in virtually every organ of the body has 
led to improved culture techniques that have overcome this 
problem for a number of cell types. Native targeted progenitor 
cells are tissue specific unipotent cells derived from most organs. 
The main advantage of native targeted progenitor cells in terms 
of regenerative medicine is that they are already programmed 
to become the cell type needed, and no in vitro differentiation 
steps are required for their use in the organ of origin. These cells 
can be obtained from the specific organ to be regenerated, ex-
panded, and used in the same patient without rejection, in an 
autologous manner [26-29,32-42]. 
  By noting the location of the progenitor cells, as well as by 
exploring the conditions that promote differentiation and/or 
self-renewal, it has been possible to overcome some of the ob-
stacles that limit cell expansion in vitro. As an example relevant 
to the treatment of neurogenic bladder and other urogenital 
disorders, urothelial cell culture has been vastly improved in 
this way. In the past, urothelial cells could be grown in the labo-
ratory setting, but with only very limited success. It was believed 
that urothelial cells had a natural senescence program that was 
hard to overcome. However, several protocols have been devel-
oped over the last two decades that have improved urothelial 
growth and expansion [34,43-45]. A system of urothelial cell 
harvesting was developed that does not use any enzymes or se-
rum and has a large expansion potential. Using these methods 
of cell culture, it is possible to expand a urothelial strain from a 
single specimen that initially covers a surface area of 1 cm
2 to 
one covering a surface area of 4,202 m
2 (the equivalent area of 
one football field) within 8 weeks [34]. 
  Now, bladder, ureter, and renal pelvic cells can all be harvest-
ed, cultured, and expanded in a similar fashion. Importantly, 
normal human bladder epithelial and muscle cells can be effi-
ciently harvested from surgical material, extensively expanded 
in culture, and their differentiation characteristics, growth re-
quirements, and other biologic properties can be studied [34,36, 
37,44-52]. However, a major concern with this approach has 
been that, in cases where cells must be expanded from a dis-
eased organ, there may no longer be enough normal cells pres-
ent in that organ to begin the process. Recent research suggests 
that this may not be correct. One important study has shown 
that cultured neuropathic bladder smooth muscle cells possess 
and maintain different characteristics than normal smooth 
muscle cells in vitro, as demonstrated by growth assays, con-
tractility and adherence tests in vitro [53]. Despite these differ-
ences, however, when neuropathic smooth muscle cells were 
cultured in vitro, and then seeded onto matrices and implanted 
in vivo, the tissue engineered constructs showed the same prop-
erties as the constructs engineered with normal cells [54]. It is 
now known that genetically normal progenitor cells, which are 
the reservoirs for new cell formation, are present even in dis-
eased tissue. These normal progenitors are programmed to give 
rise to normal tissue, regardless of whether they reside in a nor-
mal or diseased environment. Therefore, the stem cell niche and 
its role in normal tissue regeneration remains a fertile area of 
ongoing investigation. However, in some instances, primary 
autologous human cells cannot be expanded from a particular 
organ, such as the pancreas, or there is not enough normal tis-
sue remaining in the diseased organ to use for the procedures 
described above. In these situations, pluripotent human stem 
cells are envisioned to be an ideal source of cells, as they can 
differentiate into nearly any replacement tissue in the body. For 
example,embryonic stem cells exhibit the ability to proliferate 
in an undifferentiated, but still pluripotent state (self-renewal), 
as well as the ability to differentiate into a large number of spe-
cialized cell types, including genitourinary cells [55]. However, 
there are several problems associated with the use of embryonic 
stem cells in tissue engineering. Importantly, these cells tend to 
form teratomas when implanted in vivo, and this risk of tumor 
formation limits their clinical application. In addition, many 
uses of these cells are currently banned in a number of coun-
tries due to the ethical dilemmas that are associated with the 
manipulation of human embryos in culture. 
  As a result, scientists have turned to other types of pluripo-112    www.einj.or.kr
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tent cells for use in tissue engineering. These other cell types in-
clude cells derived from the adult, such as hematopoietic stem 
cells and mesenchymal stem cells [56-59], and cells derived from 
fetal sources, such as amniotic-fluid and placental-derived stem 
cells, which were discovered in 2007 [60]. Each of these cell types 
has been differentiated into epithelial and smooth muscle phe-
notypes, and thus they may have a role in genitourinary tissue 
engineering.
  Somatic cell nuclear transfer, or cloning, can serve as another 
source of pluripotent, “stem” cells that could possibly be used 
for regenerative medicine therapies. In this procedure, a nucle-
us from a somatic cell from a donor is placed into an ovum, and 
the resulting cell is induced to divide using chemicals or electric-
ity. This process produces a blastocyst that is genetically identi-
cal to the donor and can be grown in culture to produce em-
bryonic stem cell lines. These autologous stem cells have the 
potential to become almost any type of cell in the adult body, 
and thus would be useful in tissue and organ replacement ap-
plications [61]. 
  Recently, exciting reports of the successful transformation of 
adult cells into pluripotent stem cells through a type of genetic 
“reprogramming” have been published. Reprogramming is a 
technique that involves de-differentiation of adult somatic cells 
to produce patient-specific pluripotent stem cells, without the 
use of embryos. Cells generated by reprogramming would be 
genetically identical to the somatic cells (and thus, the patient 
who donated these cells) and would not be rejected. Takahashi 
and Yamanaka [62] were the first to discover that mouse fibro-
blasts could be reprogrammed into an “induced pluripotent 
state (iPS)”, and it has recently been shown that reprogramming 
of human cells is possible [63,64]. However, despite these ad-
vances, a number of questions must be answered before iPS cells 
can be used in human therapies. Although this is an exciting 
phenomenon, our understanding of the mechanisms involved 
in reprogramming is still limited.
TISSUE ENGINEERING STRATEGIES FOR 
BLADDER AUGMENTATION AND REPLACEMENT
As previously noted, the current treatment options for bladder 
augmentation or replacement are fraught with complications, 
driving the search for new therapeutic approaches [10,11]. The 
current standard of care uses gastrointestinal segments for blad-
der replacement or augmentation. However, the nature and 
function of gastrointestinal mucosa is quite different than blad-
der wall tissue, resulting in immediate and long-term complica-
tions. The bladder must store urine for prolonged periods and 
serves as a barrier to prevent highly permeable molecules elimi-
nated in urine from returning to the bloodstream. Specialized 
cells, called umbrella cells, form the permeability barrier and 
are located in the apical membrane of the urothelial lining of 
the bladder lumen. Umbrella cells are interconnected by high 
resistance tight junctions, which separate the basolateral from 
the apical cell membranes and block transepithelial ion flux [65, 
66]. In contrast, gastrointestinal tissues are designed to absorb 
solutes from the gut lumen into the bloodstream. Therefore, the 
substitution of gastrointestinal tissue for bladder tissue often 
leads to metabolic disturbances, urolithiasis, infection, perfora-
tion, and increased mucus production. Another complication 
of prolonged exposure of gastrointestinal tissue to the chemical 
composition of normal urine is malignancy [10,11,67,68]. To 
avoid these problems, urologists are participating in Food and 
Drug Administration human clinical trials to determine the 
safety and efficacy of regenerative medicine alternatives.
Biomaterial Matrices for Bladder Regeneration
Over the last few decades, several bladder wall substitutes have 
been attempted with both synthetic and organic materials. Syn-
thetic materials that have been tried in experimental and clini-
cal settings include polyvinyl sponges, Teflon, collagen matri-
ces, Vicryl (PGA) matrices, and silicone. Most of these attempts 
have failed because of mechanical, structural, functional, or 
biocompatibility problems. Usually, permanent synthetic mate-
rials used for bladder reconstruction succumb to mechanical 
failure and urinary stone formation, and use of degradable ma-
terials leads to fibroblast deposition, scarring, graft contracture, 
and a reduced reservoir volume over time [33,69].
  Because of these issues with synthetic materials, there has 
been a resurgence in the use of various collagen-based matrices 
for urological tissue regeneration. Non-seeded allogeneic acel-
lular bladder matrices have served as scaffolds for the ingrowth 
of host bladder wall components. The matrices are prepared by 
mechanically and chemically removing all cellular components 
from bladder tissue [38,70-73]. The matrices serve as vehicles 
for partial bladder regeneration, and relevant antigenicity is not 
evident.
  Cell-seeded allogeneic acellular bladder matrices have been 
used for bladder augmentation in dogs [38]. The regenerated 
bladder tissues contained a normal cellular organization con-
sisting of urothelium and smooth muscle and exhibited a nor-www.einj.or.kr    113
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mal compliance. Biomaterials preloaded with cells before their 
implantation showed better tissue regeneration compared with 
biomaterials implanted with no cells, in which tissue regenera-
tion depended on ingrowth of the surrounding tissue. The blad-
ders showed a significant increase (100%) in capacity when 
augmented with scaffolds seeded with cells, compared to scaf-
folds without cells (30%). The acellular collagen matrices can be 
enhanced with growth factors to improve bladder regeneration 
[74].
  Small intestinal submucosa (SIS), a biodegradable, acellular, 
xenogeneic collagen-based tissue-matrix graft, was first de-
scribed in the 1980’s as an acellular matrix for tissue replacement 
in the vascular field [75]. It has been shown to promote regener-
ation of a variety of host tissues, including blood vessels and lig-
aments [76]. The matrix is derived from pig small intestine in 
which the mucosa is mechanically removed from the inner sur-
face and the serosa and muscular layer are removed from the 
outer surface. Animal studies have shown that the non-seeded 
SIS matrix used for bladder augmentation is able to regenerate 
in vivo [77,78]. Histologically, the transitional layer was the same 
as that of the native bladder tissue, but, as with other non-seeded 
collagen matrices used experimentally, the muscle layer was not 
fully developed. A large amount of collagen was interspersed 
among a smaller number of muscle bundles. A computer-assist-
ed image analysis demonstrated a decreased muscle-to-collagen 
ratio with loss of the normal architecture in the SIS-regenerated 
bladders. In vitro contractility studies performed on the SIS-re-
generated dog bladders showed a decrease in maximal contrac-
tile response by 50% from those of normal bladder tissues. Ex-
pression of muscarinic, purinergic, and alpha-adrenergic recep-
tors and functional cholinergic and purinergic innervation were 
demonstrated [78]. Cholinergic and purinergic innervation also 
occurred in rats [79]. 
  Bladder augmentation using laparoscopic techniques was 
performed on minipigs with porcine bowel acellular tissue ma-
trix, human placental membranes, or porcine SIS. At 12 weeks 
post-operatively the grafts had contracted to 70%, 65%, and 
60% of their original sizes, respectively, and histologically the 
grafts showed predominantly only mucosal regeneration [80]. 
The same group evaluated the long-term results of laparoscopic 
hemicystectomy and bladder replacement with SIS with ureter-
al reimplantation into the SIS material in minipigs. Histopa-
thology studies after 1 year showed muscle at the graft periph-
ery and center but it consisted of small fused bundles with sig-
nificant fibrosis. Nerves were present at the graft periphery and 
center but they were decreased in number. Compared to pri-
mary bladder closure after hemi-cystectomy, no advantage in 
bladder capacity or compliance was documented [81]. More re-
cently, bladder regeneration has been shown to be more reliable 
when the SIS was derived from the distal ileum [82].
  In summary, the multiple studies using various materials as 
non-seeded grafts for cystoplasty indicate that when biomateri-
als are used alone, small defects can be repaired, but in the repair 
of large defects, the urothelial layer was able to regenerate nor-
mally, but the muscle layer, although present, was not fully de-
veloped [38,70,71,78,83,84]. Studies involving acellular matrices 
that may provide the necessary environment to promote muscle 
cell migration, growth, and differentiation are being conducted 
[18]. With continued research in this area, these matrices may 
have a clinical role in bladder replacement in the future.
Regenerative Medicine for Bladder Using Cell 
Transplantation
Regenerative medicine with selective cell transplantation may 
provide a means to create functional new bladder segments. 
The success of cell transplantation strategies for bladder recon-
struction depends on the ability to use donor tissue efficiently 
and to provide the right conditions for long-term survival, dif-
ferentiation, and growth. Various cell sources have been explored 
for bladder regeneration. Native cells are currently preferable 
due to their autologous source [34]. It has been shown experi-
mentally that the bladder neck and trigone area has a higher 
propensity of urothelial progenitor cells [85], and these cells are 
localized in the basal region [86]. Amniotic fluid and bone 
marrow-derived stem cells can also be used in an autologous 
manner and have the potential to differentiate into bladder 
muscle [60,87] and urothelium [88]. Embryonic stem cells also 
have the potential to differentiate into bladder tissue [89], al-
though their use is currently banned in many countries for this 
purpose. Most recently, however, it has been shown that pro-
genitor cells can be derived from voided urine, and these cells 
are also able to differentiate into urothelial and smooth muscle 
cells, making them an extremely attractive option for bladder 
engineering [90,91].
  Regardless of their source, it has been shown that human 
urothelial and muscle cells can be expanded in vitro, seeded onto 
polymer scaffolds, and allowed to attach and form sheets of cells. 
The cell-polymer scaffold can then be implanted in vivo. Histo-
logic analysis indicated that viable cells were able to self assem-
ble back into their respective tissue types, and retained their na-114    www.einj.or.kr
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tive phenotype [28]. 
  As described above, it has been shown that the urothelium is 
able to regenerate generously over free grafts, most likely be-
cause the urothelium is associated with a high reparative capac-
ity [92]. However, bladder muscle tissue is less likely to regener-
ate in a normal fashion. As a result of this discovery, it was hy-
pothesized that building a three-dimensional bladder construct 
in vitro, before implantation, would facilitate the eventual termi-
nal differentiation of the cells after implantation in vivo and 
would minimize the inflammatory response toward the matrix, 
thus avoiding graft contracture and shrinkage. The dog study 
described earlier supports this hypothesis and illustrates a major 
difference between matrices used with autologous cells (tissue-
engineered matrices) and those used without cells [38]. Matri-
ces that were seeded with cells and then used for bladder aug-
mentation retained most of their preimplantation diameter, as 
opposed to matrices implanted without cells, in which signifi-
cant graft contraction and shrinkage occurred. In addition, his-
tological analysis demonstrated a marked paucity of muscle 
cells and a more aggressive inflammatory reaction in the matri-
ces implanted without cells. 
  The results of these initial studies showed that the creation of 
artificial bladders may be achieved in vivo; however, it could not 
be determined whether the functional parameters noted were 
created by the augmented segment or by the remaining native 
bladder tissue. To better address this question, an animal model 
was designed in which subtotal cystectomies followed by re-
placement with a tissue-engineered organ were performed [41]. 
Cystectomy-only controls and animals that received bladder re-
placements made from non-seeded matrices maintained aver-
age capacities of 22% and 46% of preoperative values, respec-
tively. However, an average bladder capacity of 95% of the origi-
nal precystectomy volume was achieved in animals receiving 
cell-seeded tissue engineered bladder replacements. These find-
ings were confirmed radiographically. The subtotal cystectomy 
reservoirs that were not reconstructed and the polymer-only 
reconstructed bladders showed a marked decrease in bladder 
compliance (10% and 42% total compliance). In contrast, the 
compliance of the cell-seeded tissue-engineered bladders showed 
almost no difference from preoperative values that were mea-
sured when the native bladder was present (106%). Histologi-
cally, the non-seeded bladder replacement scaffolds presented a 
pattern of normal urothelial cells with a thickened fibrotic sub-
mucosa and a thin layer of muscle fibers. The tissue-engineered 
bladders (scaffold + cells) showed a normal cellular organiza-
tion, consisting of a trilayer of urothelium, submucosa, and 
muscle. Immunocytochemical analyses confirmed the muscle 
and urothelial phenotype. S-100 staining indicated the presence 
of neural structures [41]. These studies have been repeated by 
other investigators, and they obtained similar results using larg-
er numbers of animals over the long-term [83,93]. Thus, the 
strategy of using biodegradable scaffolds seeded with cells can 
be pursued without concerns for local or systemic toxicity [94]. 
  However, not all scaffold materials perform well if a large 
portion of the bladder must be replaced. In a study using SIS 
for subtotal bladder replacement in dogs, both the unseeded 
and cell seeded experimental groups showed graft shrinkage 
and poor results [95]. This confirms that the type of scaffold 
used in the construction of tissue-engineered bladders is critical 
for the success of these technologies. The use of bioreactors, 
which provide mechanical stimulation for the growing organ in 
vitro, has also been proposed as an important parameter for 
success [96]. Bioreactors provide can provide mechanical stim-
ulation such as periodic stretching of the tissue, which has been 
shown to assist in in vitro muscle development, and exposure to 
flow conditions, which is important for the development of en-
dothelial layers in blood vessels and hollow organs such as the 
bladder. In fact, Farhat and Yeger [96] have developed bioreac-
tor systems specifically for bladder development. These systems 
provide simulated filling/emptying functions to the engineered 
tissue, and this may lead to a bladder construct with more func-
tionality.
  A clinical experience involving engineered bladder tissue for 
cystoplasty was conducted starting in 1998. A small pilot study 
of seven patients reported the use of either collagen scaffolds 
seeded with cells or a combined PGA-collagen scaffold seeded 
with cells for bladder replacement. These engineered tissues 
were implanted with or without omental coverage (Fig. 1). Pa-
tients reconstructed with engineered bladder tissue created 
with cell-seeded PGA-collagen scaffolds and omental coverage 
showed increased compliance, decreased end-filling pressures, 
increased capacities and longer dry periods over time (Fig. 2) 
[97]. This experience suggests that the engineered bladders 
continue to improve with time, mirroring their continued de-
velopment. Although the experience is promising and shows 
that engineered tissues can be implanted safely, it was just a first 
step towards the goal of engineering fully functional bladders. 
Two multi-center Phase II clinical studies, the first involving 
pediatric patients with neurogenic bladder secondary to spina 
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bladder secondary to spinal cord injury, were then undertaken 
to evaluate the safety and effectiveness of the tissue-engineered 
Neo-Bladder Augment (NBA). The spina bifida study involved 
10 patients (mean age 8.2 years, 6 females/4 males) at 4 medical 
centers in the United States who required augmentation cysto-
plasty due to bladder pressures ≥40 cmH2O and/or develop-
ment of upper urinary tract changes such as hydronephrosis or 
vesicoureteral reflux. Each patient underwent an open bladder 
biopsy, and autologous cells derived from the biopsy were ex-
panded in vitro and seeded onto the NBA scaffold. This con-
struct was then implanted into each patient. The procedure was 
well-tolerated and 6 of the 10 patients showed clinical improve-
ment based on urodynamics studies, radiography, and voiding 
diary results. The second study involved 6 patients over the age 
of 18 with severe bladder dysfunction secondary to spinal cord 
injury. The same procedure was performed to create the im-
plantable construct from the patients’ cells and the NBA scaf-
fold, and after 2 years of follow-up, it was found that 4 of the 6 
patients responded well to the tissue-engineered bladder. How-
ever, both studies highlighted an important issue in bladder re-
generation. In both studies, the implants placed patients who 
were able to undergo normal bladder cycling (filling and emp-
tying) regenerated well, while those implanted in patients who 
did not have normal bladder cycles due open bladder necks or 
other physiological issues did not respond as well to this thera-
py. This further supports the idea that conditioning engineered 
Fig. 1. Construction of engineered bladder. (A) Scaffold material seeded with cells for use in bladder repair. (B) The seeded scaffold is 
anastamosed to native bladder with running 4-0 polyglycolic sutures. (C) Implant covered with fibrin glue and omentum.
A B C
Fig. 2. Cystograms and urodynamic studies of a patient before and after implantation of the tissue engineered bladder. (A) Preopera-
tive results indicate an irregular-shaped bladder in the cystogram (left) and abnormal bladder pressures as the bladder is filled during 
urodynamic studies (right). (B) Postoperatively, findings are significantly improved. Pves, intravesical pressure. (Reprinted from Atala 
A, Bauer SB, Soker S, Yoo JJ, Retik AB. Lancet 2006;367:1241-6, with permission of Elsevier Limited [97]).
Pves
Pves
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bladder tissue within a specially designed bioreactor prior to 
implantation may lead to improved clinical results.
CONCLUSIONS
Regenerative medicine approaches are currently being devel-
oped for every type of tissue and organ within the urinary sys-
tem. Most of the progress within this field has occurred within 
the last decade. A pipeline of regenerative medicine technolo-
gies now exists with products in the discovery stage, preclinical 
testing, and clinical trials. Research is underway to expand both 
cell source and biomaterial options for regenerative medicine 
applications. Recent progress has established the feasibility of 
using regenerative medicine to treat neurogenic bladder and 
the future promises that regenerative medical treatment options 
will expand to patients with other bladder diseases, as well as to 
patients requiring replacement of other organs throughout the 
body. 
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